Stockscreener 앱 받기
9.35
0.11%
-0.010
전일 마감가:
$9.36
열려 있는:
$9.39
하루 거래량:
684.81K
Relative Volume:
0.75
시가총액:
$476.92M
수익:
$20.72M
순이익/손실:
$-100.84M
주가수익비율:
-3.515
EPS:
-2.66
순현금흐름:
$-78.56M
1주 성능:
+4.00%
1개월 성능:
+18.96%
6개월 성능:
+40.18%
1년 성능:
+98.09%
1일 변동 폭
$9.28
$9.78
1주일 범위
$8.66
$9.78
52주 변동 폭
$2.235
$12.34
4D몰큘러 테라퓨틱스 Stock (FDMT) Company Profile
명칭
4 D Molecular Therapeutics Inc
전화
(510) 505-2680
주소
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
9.35 | 477.43M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
4D몰큘러 테라퓨틱스 Stock (FDMT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 재개 | Barclays | Overweight |
| 2025-11-07 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2025-01-13 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2024-11-21 | 개시 | Morgan Stanley | Underweight |
| 2024-09-23 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-04-15 | 개시 | Barclays | Overweight |
| 2024-02-07 | 재개 | Goldman | Buy |
| 2023-10-26 | 개시 | RBC Capital Mkts | Outperform |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-18 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2023-07-05 | 개시 | Chardan Capital Markets | Buy |
| 2023-01-30 | 개시 | BMO Capital Markets | Outperform |
| 2022-11-18 | 개시 | H.C. Wainwright | Buy |
| 2022-11-15 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-12 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2022-06-22 | 개시 | Jefferies | Buy |
| 2022-01-04 | 개시 | SVB Leerink | Outperform |
| 2021-01-05 | 개시 | BofA Securities | Buy |
| 2021-01-05 | 개시 | Evercore ISI | Outperform |
| 2021-01-05 | 개시 | Goldman | Neutral |
모두보기
4D몰큘러 테라퓨틱스 주식(FDMT)의 최신 뉴스
4DMT Announces New Employment Inducement Grants - Yahoo Finance Singapore
4D Molecular Therapeutics Advances Toward Phase 3 Milestones in Retina Gene Therapy - AD HOC NEWS
Barclays flags M&A tailwinds and pricing relief as upside catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - MSN
Will 4D Molecular Therapeutics Inc. stock attract ESG investorsJuly 2025 Analyst Calls & Expert Verified Stock Movement Alerts - mfd.ru
Will 4D Molecular Therapeutics Inc. benefit from geopolitical trends2025 Institutional Moves & Smart Allocation Stock Reports - mfd.ru
What are analysts’ price targets for 4D Molecular Therapeutics Inc.2025 Support & Resistance & Entry Point Strategy Guides - mfd.ru
4D Molecular (FDMT) Completes Enrollment for Key Phase 3 Wet AMD Trial - GuruFocus
Wet AMD trial fills fast as 4D-150 targets fewer eye injections - Stock Titan
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Barclays Flags M&A Tailwinds and Pricing Relief as Upside Catalysts for 4D Molecular Therapeutics, Inc. (FDMT) - Finviz
Barclays Initiates Coverage of 4D Molecular Therapeutics (FDMT) with Overweight Recommendation - Nasdaq
Deep Dive Into 4D Molecular Therapeutics Stock: Analyst Perspectives (5 Ratings) - Benzinga
Barclays Initiates Coverage on 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
4D Molecular Therapeutics Restructures Equity via Warrant Exchange - TipRanks
4D Molecular Therapeutics: A Valuation Disconnect Amidst Clinical Progress - AD HOC NEWS
4D Molecular (FDMT) Grants RSUs to New Employees - GuruFocus
4D Molecular Therapeutics Grants 23,600 RSUs to New Employees - Intellectia AI
Biotech 4DMT hands 23,600 stock units to four new hires under award plan - Stock Titan
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Update - MarketBeat
FDMT: 4D-150 gene therapy shows strong safety, efficacy, and commercial potential in retinal disease - TradingView
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Is 4D Molecular Therapeutics Inc. stock ready for breakoutJuly 2025 Intraday Action & Fast Moving Stock Trade Plans - ulpravda.ru
Is 4D Molecular Therapeutics Inc. stock a buy on dipsJuly 2025 Setups & Free Long-Term Investment Growth Plans - Улправда
Why 4D Molecular Therapeutics Inc. stock appeals to dividend seekersMarket Weekly Review & Low Drawdown Investment Strategies - Улправда
Stock Report: Can 4D Molecular Therapeutics Inc. stock double in next 5 years2025 Analyst Calls & Daily Technical Stock Forecast Reports - ulpravda.ru
Smart Money: Is 4D Molecular Therapeutics Inc. stock a safe investment in uncertain marketsJuly 2025 Trade Ideas & Free Reliable Trade Execution Plans - Улправда
Will 4D Molecular Therapeutics Inc. stock gain from strong economyJuly 2025 Outlook & High Return Stock Watch Alerts - ulpravda.ru
Can 4D Molecular Therapeutics Inc. stock double in next 5 yearsJuly 2025 Institutional & Risk Controlled Swing Alerts - Улправда
Is 4D Molecular Therapeutics Inc. stock a top momentum play2025 Volatility Report & High Accuracy Swing Trade Signals - Улправда
Los Angeles Daily News4D Molecular Therapeutics, Inc.Common Stock (Nasdaq:FDMT) Stock Quote - FinancialContent
4D Molecular Therapeutics, Inc. Announces Executive Changes - marketscreener.com
4DMT Provides Company Update and Anticipated Development Milestones for 2026 - The Manila Times
4D Molecular Therapeutics Announces Key Management Changes - TradingView — Track All Markets
4D Molecular Therapeutics expands phase 3 trial enrollment - MSN
Certain Restricted Stock Units of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - MarketScreener
Certain Options of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com
Certain Common Stock of 4D Molecular Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-JAN-2026. - marketscreener.com
4D Molecular falls after early-stage trial data for cystic fibrosis therapy - MSN
Why Everyone Is Watching 4D Molecular Therapeutics, Inc. (FDMT) Closely - Finviz
Ashoo Gupta of 4D Molecular Therapeutics sells $3.3k in FDMT stock - Investing.com Nigeria
4D Molecular Therapeutics, Inc.'s (NASDAQ:FDMT) institutional investors lost 20% over the past week but have profited from longer-term gains - Yahoo Finance
4D Molecular Therapeutics Gains Momentum from Clinical Data and Index Inclusion - AD HOC NEWS
4D Molecular Therapeutics, Inc.(NasdaqGS:FDMT) added to S&P Biotechnology Select Industry Index - marketscreener.com
How interest rate cuts could boost 4D Molecular Therapeutics Inc. stockJuly 2025 Chart Watch & Accurate Buy Signal Notifications - Улправда
Is 4D Molecular Therapeutics Stock Built to Withstand More Downside? - Trefis
Analysts Offer Insights on Healthcare Companies: Xenon (XENE) and 4D Molecular Therapeutics (FDMT) - The Globe and Mail
4D Molecular Therapeutics Executive Sells Shares - TradingView — Track All Markets
4D Molecular Therapeutics: Jury Still Out On CF Gene Therapy After Dense Data Drop (NASDAQ:FDMT) - Seeking Alpha
4D몰큘러 테라퓨틱스 (FDMT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):